2020
Comparative analysis of prognostic histopathologic parameters in subtypes of epithelioid pleural mesothelioma
Bilecz A, Stockhammer P, Theegarten D, Kern I, Jakopovic M, Samarzija M, Klikovits T, Hoda MA, Döme B, Oberndorfer F, Muellauer L, Fillinger J, Kovács I, Pirker C, Schuler M, Plönes T, Aigner C, Klepetko W, Berger W, Brcic L, Laszlo V, Hegedus B. Comparative analysis of prognostic histopathologic parameters in subtypes of epithelioid pleural mesothelioma. Histopathology 2020, 77: 55-66. PMID: 32170970, DOI: 10.1111/his.14105.Peer-Reviewed Original ResearchConceptsMalignant pleural mesotheliomaEpithelioid malignant pleural mesotheliomaOverall survivalHistological subtypesPleural mesotheliomaIntensive multimodal treatment approachesEpithelioid pleural mesotheliomaIndependent prognostic factorShorter overall survivalHigh nuclear gradeMultimodal treatment approachCancer Genome Atlas (TCGA) databaseNuclear grading systemLonger OSPrognostic factorsPrognostic impactPrognostic roleRare malignancyDismal prognosisTrabecular variantMultimodal treatmentPrognostic significancePatient cohortHistopathologic parametersMultimodal therapy
2019
Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma
Stockhammer P, Ploenes T, Theegarten D, Schuler M, Maier S, Aigner C, Hegedus B. Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma. Lung Cancer 2019, 139: 124-132. PMID: 31778960, DOI: 10.1016/j.lungcan.2019.11.013.Peer-Reviewed Original ResearchConceptsMalignant pleural mesotheliomaNon-malignant pleural diseasePleural effusionMPM patientsPleural mesotheliomaPrognostic stratificationNon-epithelioid malignant pleural mesotheliomaStage IV lung cancerEpithelioid malignant pleural mesotheliomaInferior overall survivalTGF-β levelsLevels of TGFLung cancer patientsChest CT scanOverall survivalSMRP levelsClinicopathological characteristicsDismal prognosisPleural diseaseTumor loadAggressive malignancyDisease stageCancer patientsLung cancerPrimary diagnosis
2016
Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma – A multi-institutional study
Hoda MA, Dong Y, Rozsas A, Klikovits T, Laszlo V, Ghanim B, Stockhammer P, Ozsvar J, Jakopovic M, Samarzija M, Brcic L, Bendek M, Szirtes I, Reid G, Kirschner MB, Kao SC, Opitz I, Weder W, Frauenfelder T, Nguyen-Kim TD, Aigner C, Klepetko W, van Zandwijk N, Berger W, Dome B, Grusch M, Hegedus B. Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma – A multi-institutional study. European Journal Of Cancer 2016, 63: 64-73. PMID: 27288871, DOI: 10.1016/j.ejca.2016.04.018.Peer-Reviewed Original ResearchConceptsMalignant pleural mesotheliomaActivin A levelsMPM patientsActivin APleural mesotheliomaHigh activin A levelsNon-malignant pleural diseaseEpithelioid malignant pleural mesotheliomaEpithelioid MPM patientsTime of diagnosisLonger overall survivalNovel prognostic biomarkerMulti-institutional studyEnzyme-linked immunosorbent assayA levelsPlasma activinOverall survivalSurgical resectionActivin expressionHigh activinPleural diseasePoor prognosisClinicopathological variablesEpithelioid histologyHealthy controls